Serum total and free prostate-specific antigen for breast cancer diagnosis in women

Margot H. Black, Maurizia Giai, Riccardo Ponzone, Piero Sismondi, He Yu, Eleftherios P. Diamandis

Research output: Contribution to journalArticle

Abstract

Prostate-specific antigen (PSA) is a serine protease expressed at high levels in prostate epithelium, and elevated PSA in serum is a well- established marker of prostate cancer. Recently, the relative proportions of free PSA and PSA complexed to the serine protease inhibitor α1- antichymotrypsin have become important variables in distinguishing between prostate cancer and benign prostatic hyperplasia. Numerous studies have demonstrated the production of PSA in female tissues such as the breast, and low levels of PSA are present in female sera. The objective of this study was to measure and compare the relative proportions of free PSA and PSA complexed to the serine protease inhibitor α1-antichymotrypsin in the serum of women with breast cancer or benign breast disease or women with no known malignancies. PSA was measured with an established immunoassay for total PSA and a novel immunoassay for free PSA, both of which had a detection limit of 0.001 μg/liter (1 ng/liter). The percentage of breast cancer patients with free PSA as the predominant molecular form (>50% of total PSA) in serum was five times higher than that of healthy women or women with benign breast disease, and PSA decreased in the serum of breast cancer patients after surgery. The diagnostic use of free PSA for breast cancer is limited at this point, due to the low diagnostic sensitivity (~20%); however, free PSA as the predominant molecular form shows a high diagnostic specificity (~96%) in comparison to women free of breast cancer or with benign breast disease. These results suggest that the clinical applicability of free PSA for breast cancer diagnosis and the biological mechanism behind its increase should be further investigated.

Original languageEnglish
Pages (from-to)467-473
Number of pages7
JournalClinical Cancer Research
Volume6
Issue number2
Publication statusPublished - Feb 2000

Fingerprint

Prostate-Specific Antigen
Breast Neoplasms
Serum
Breast Diseases
Serine Proteinase Inhibitors
Immunoassay
Prostatic Neoplasms
Prostatic Hyperplasia
Serine Proteases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Black, M. H., Giai, M., Ponzone, R., Sismondi, P., Yu, H., & Diamandis, E. P. (2000). Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clinical Cancer Research, 6(2), 467-473.

Serum total and free prostate-specific antigen for breast cancer diagnosis in women. / Black, Margot H.; Giai, Maurizia; Ponzone, Riccardo; Sismondi, Piero; Yu, He; Diamandis, Eleftherios P.

In: Clinical Cancer Research, Vol. 6, No. 2, 02.2000, p. 467-473.

Research output: Contribution to journalArticle

Black, MH, Giai, M, Ponzone, R, Sismondi, P, Yu, H & Diamandis, EP 2000, 'Serum total and free prostate-specific antigen for breast cancer diagnosis in women', Clinical Cancer Research, vol. 6, no. 2, pp. 467-473.
Black, Margot H. ; Giai, Maurizia ; Ponzone, Riccardo ; Sismondi, Piero ; Yu, He ; Diamandis, Eleftherios P. / Serum total and free prostate-specific antigen for breast cancer diagnosis in women. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 2. pp. 467-473.
@article{7e86d90aa60c48c6abd913f4b318c302,
title = "Serum total and free prostate-specific antigen for breast cancer diagnosis in women",
abstract = "Prostate-specific antigen (PSA) is a serine protease expressed at high levels in prostate epithelium, and elevated PSA in serum is a well- established marker of prostate cancer. Recently, the relative proportions of free PSA and PSA complexed to the serine protease inhibitor α1- antichymotrypsin have become important variables in distinguishing between prostate cancer and benign prostatic hyperplasia. Numerous studies have demonstrated the production of PSA in female tissues such as the breast, and low levels of PSA are present in female sera. The objective of this study was to measure and compare the relative proportions of free PSA and PSA complexed to the serine protease inhibitor α1-antichymotrypsin in the serum of women with breast cancer or benign breast disease or women with no known malignancies. PSA was measured with an established immunoassay for total PSA and a novel immunoassay for free PSA, both of which had a detection limit of 0.001 μg/liter (1 ng/liter). The percentage of breast cancer patients with free PSA as the predominant molecular form (>50{\%} of total PSA) in serum was five times higher than that of healthy women or women with benign breast disease, and PSA decreased in the serum of breast cancer patients after surgery. The diagnostic use of free PSA for breast cancer is limited at this point, due to the low diagnostic sensitivity (~20{\%}); however, free PSA as the predominant molecular form shows a high diagnostic specificity (~96{\%}) in comparison to women free of breast cancer or with benign breast disease. These results suggest that the clinical applicability of free PSA for breast cancer diagnosis and the biological mechanism behind its increase should be further investigated.",
author = "Black, {Margot H.} and Maurizia Giai and Riccardo Ponzone and Piero Sismondi and He Yu and Diamandis, {Eleftherios P.}",
year = "2000",
month = "2",
language = "English",
volume = "6",
pages = "467--473",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Serum total and free prostate-specific antigen for breast cancer diagnosis in women

AU - Black, Margot H.

AU - Giai, Maurizia

AU - Ponzone, Riccardo

AU - Sismondi, Piero

AU - Yu, He

AU - Diamandis, Eleftherios P.

PY - 2000/2

Y1 - 2000/2

N2 - Prostate-specific antigen (PSA) is a serine protease expressed at high levels in prostate epithelium, and elevated PSA in serum is a well- established marker of prostate cancer. Recently, the relative proportions of free PSA and PSA complexed to the serine protease inhibitor α1- antichymotrypsin have become important variables in distinguishing between prostate cancer and benign prostatic hyperplasia. Numerous studies have demonstrated the production of PSA in female tissues such as the breast, and low levels of PSA are present in female sera. The objective of this study was to measure and compare the relative proportions of free PSA and PSA complexed to the serine protease inhibitor α1-antichymotrypsin in the serum of women with breast cancer or benign breast disease or women with no known malignancies. PSA was measured with an established immunoassay for total PSA and a novel immunoassay for free PSA, both of which had a detection limit of 0.001 μg/liter (1 ng/liter). The percentage of breast cancer patients with free PSA as the predominant molecular form (>50% of total PSA) in serum was five times higher than that of healthy women or women with benign breast disease, and PSA decreased in the serum of breast cancer patients after surgery. The diagnostic use of free PSA for breast cancer is limited at this point, due to the low diagnostic sensitivity (~20%); however, free PSA as the predominant molecular form shows a high diagnostic specificity (~96%) in comparison to women free of breast cancer or with benign breast disease. These results suggest that the clinical applicability of free PSA for breast cancer diagnosis and the biological mechanism behind its increase should be further investigated.

AB - Prostate-specific antigen (PSA) is a serine protease expressed at high levels in prostate epithelium, and elevated PSA in serum is a well- established marker of prostate cancer. Recently, the relative proportions of free PSA and PSA complexed to the serine protease inhibitor α1- antichymotrypsin have become important variables in distinguishing between prostate cancer and benign prostatic hyperplasia. Numerous studies have demonstrated the production of PSA in female tissues such as the breast, and low levels of PSA are present in female sera. The objective of this study was to measure and compare the relative proportions of free PSA and PSA complexed to the serine protease inhibitor α1-antichymotrypsin in the serum of women with breast cancer or benign breast disease or women with no known malignancies. PSA was measured with an established immunoassay for total PSA and a novel immunoassay for free PSA, both of which had a detection limit of 0.001 μg/liter (1 ng/liter). The percentage of breast cancer patients with free PSA as the predominant molecular form (>50% of total PSA) in serum was five times higher than that of healthy women or women with benign breast disease, and PSA decreased in the serum of breast cancer patients after surgery. The diagnostic use of free PSA for breast cancer is limited at this point, due to the low diagnostic sensitivity (~20%); however, free PSA as the predominant molecular form shows a high diagnostic specificity (~96%) in comparison to women free of breast cancer or with benign breast disease. These results suggest that the clinical applicability of free PSA for breast cancer diagnosis and the biological mechanism behind its increase should be further investigated.

UR - http://www.scopus.com/inward/record.url?scp=0033970144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033970144&partnerID=8YFLogxK

M3 - Article

C2 - 10690525

AN - SCOPUS:0033970144

VL - 6

SP - 467

EP - 473

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -